Pelthos Therapeutics Strengthens Leadership Team, Appoints Andrew Einhorn To Board Of Directors

Pelthos Therapeutics Inc., a biopharmaceutical company focused on commercializing innovative therapies for patients with unmet medical needs, has announced the appointment of Andrew J. Einhorn to its Board of Directors, effective immediately. His term will continue until the company’s 2026 annual meeting of shareholders, after which he will remain in the role until a successor is elected and qualified, or until he resigns or is removed. Along with joining the Board, Mr. Einhorn will also serve on the Audit Committee and the Compensation Committee.

Andrew J. Einhorn brings more than 40 years of experience in corporate financial management. His background spans investment banking, capital markets, and senior finance leadership roles at several clinical and commercial-stage life science companies. This broad expertise positions him well to support Pelthos as it continues to evolve as a commercially focused organization.

Peter Greenleaf, Chairman of the Board, stated that Mr. Einhorn’s deep understanding of capital markets and his extensive in-house finance experience make him a strong addition to the Board. He noted that Mr. Einhorn has played key roles in driving growth at multiple public and private life science companies, and that this experience will be important as Pelthos continues to expand.

With this appointment, the Pelthos Board now consists of eight directors.

Mr. Einhorn currently serves as a consultant at Danforth Advisors, where he provides strategic financial guidance to both public and private life science companies. Throughout his career in the biotechnology sector, he has held Chief Financial Officer positions at several organizations, including ESP Pharma, Esprit Pharma, Oceana Therapeutics, Edge Therapeutics, and RVL Pharmaceuticals. Prior to his work in the biotech industry, he spent more than two decades in investment banking and capital markets. He also serves as a venture advisor to the Israel Biotech Fund.

In response to his appointment, Mr. Einhorn expressed enthusiasm about joining the Pelthos Board of Directors. He said he looks forward to working with the company’s leadership team and believes Pelthos has already made strong progress as a newly public company. He added that he is eager to contribute to the company’s mission and future growth.